Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.05.29.20109199: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Patients with confirmed SARS-CoV-2 infection, who gave informed consent and had no contraindications for IFN treatment described in the product information sheet, received therapy as approved in the Cuban COVID protocol.
IRB: The protocol of this study was evaluated and approved by a centralized Research Ethics Committee, representing all hospital institutions enrolled in the diagnosis and treatment of patients.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. …
SciScore for 10.1101/2020.05.29.20109199: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Patients with confirmed SARS-CoV-2 infection, who gave informed consent and had no contraindications for IFN treatment described in the product information sheet, received therapy as approved in the Cuban COVID protocol.
IRB: The protocol of this study was evaluated and approved by a centralized Research Ethics Committee, representing all hospital institutions enrolled in the diagnosis and treatment of patients.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The limitations of this open, non-randomized observational study include unbalanced demographics between treatment arms of unequal size. Nevertheless, the purpose of this study was to rapidly evaluate if inclusion of IFN-α2b at the doses and therapeutic regimen employed, offered a therapeutic benefit to COVID-19 cases. Recent publications suggest that treatment with chloroquine16 or lopinavir/ritonavir11 may offer little therapeutic benefit in COVID-19. With this information, we postulate that IFN treatment is likely the active antiviral in the regimen employed. Regardless of the identified limitations, therefore, our findings suggest that IFN-α2b treatment may be effective for the treatment of COVID-19
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04292899 Completed Study to Evaluate the Safety and Antiviral Activity of Remde… NCT04292730 Completed Study to Evaluate the Safety and Antiviral Activity of Remde… NCT04257656 Terminated A Trial of Remdesivir in Adults With Severe COVID-19 NCT04252664 Suspended A Trial of Remdesivir in Adults With Mild and Moderate COVID… NCT04280705 Completed Adaptive COVID-19 Treatment Trial (ACTT) Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
